Hungarian pharmaceutical company Gedeon Richter and Japanese company Fuji Pharma are expanding their long-term partnership. The expanded collaboration will focus on the research, development, and marketing of innovative gynecological therapies.
In a statement published on Tuesday on the Budapest Stock Exchange (BÉT) website, Gedeon Richter Nyrt. (Richter) and Fuji Pharma Co., Ltd. (Fuji) announced that they are significantly strengthening their strategic alliance. Both companies are thus consolidating their position in a market segment that is considered under-served globally, namely women’s healthcare (WHC).
The cooperation between the long-established Hungarian company and the Japanese specialist has been in place for several years. Successful milestones in this collaboration include:
- Alyssa®: A drug developed in Japan based on drospirenone and estetrol (E4) for the treatment of dysmenorrhea.
- Nextstellis™: An innovative oral contraceptive already marketed in Thailand.
- FYLREVY®: A hormone replacement therapy candidate for which Fuji holds the marketing rights in Japan and the ASEAN countries and which recently received a positive recommendation from the European CHMP committee.
Despite its high relevance, gynecology accounts for less than 5% of total pharmaceutical research and development worldwide. Richter and Fuji see this innovation gap as an opportunity. The signed business cooperation agreement provides for the partners to pool their expertise to identify and evaluate external drug candidates and bring them to market maturity through acquisitions or in-licensing.
To increase the pace of innovation, Richter is pursuing an international research strategy. In addition to strengthening R&D activities at its headquarters in Budapest, a specialized research center for original gynecological research was recently opened in Belgium. This center will play a key role in joint projects with Fuji Pharma.
Our collaboration reflects our commitment to finding solutions for significant, previously unmet needs in gynecology and improving the quality of life for millions of women worldwide,” said Dr. Péter Turek, Head of Gynecology at Richter, emphasizing the importance of the alliance.
Satoshi Suzuki, Head of the Corporate Strategy Division at Fuji, was also optimistic. “By combining our strengths, we want to create value faster and more broadly. Our goal is to achieve tangible results for women’s health worldwide,” he explained.
For Gedeon Richter, deepening its partnership with Fuji Pharma represents a further step toward consolidating its global market leadership in gynecology.
The combination of Richter’s European research capabilities and Fuji’s strong presence in the Asia-Pacific region creates a powerful network for future product launches.
Related article
Pharma Giant Richter’s Shares Surge after U.S. Drug Approval
The approvals mark an important milestone accomplishment for the pharma giant as its first FDA-approved biosimilars.Continue reading
Via bet.hu; Featured image: Hungary Today
